Business Wire

Boyd Watterson & Amber Infrastructure Jointly Announce Strategic Transaction

Share

Boyd Watterson Asset Management, LLC (“Boyd Watterson”) (www.boydwatterson.com) and Amber Infrastructure Group Holdings Limited (“Amber”) (www.amberinfrastructure.com) jointly announced that the businesses will come together under a common parent company to create a global diversified Real Estate, Infrastructure, and Fixed Income asset management platform (the “Company”). Upon closing, the Company through its operating subsidiaries will be a premier global alternatives investment manager with over three-hundred investment personnel, offices in eight US cities and twelve countries. The firm will have approximately $35.7 billion in assets under management. While the financial terms of the transaction have not been disclosed, the Company’s shareholders upon closing will be comprised of the existing shareholders in Boyd Watterson and Amber.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530809315/en/

Founded in 1928 by its predecessor firm, Boyd Watterson is headquartered in Cleveland, OH and has $18.2 billion in total assets under management (“AUM”) across its Real Estate and Fixed Income investment portfolios. Boyd has a reputation for creating bespoke investment solutions that deliver attractive, risk-adjusted returns to its clients.

Founded in 2009, Amber is headquartered in London, UK and oversees £14 billion or approximately US$17.5 billion in AUM. Amber specializes in mobilizing private capital to deliver essential infrastructure projects globally across sectors.

Hunt Companies (www.huntcompanies.com), an investor in both companies, recognized the complementary businesses and facilitated the transaction.

“With the combination of Amber Infrastructure Group, we are broadening our scope and opening up exciting new investment opportunities for our clients,” said Brian Gevry, CEO of Boyd Watterson. “We are both recognized leaders in our asset classes with exceptional talent who continually strive to outperform customer expectations. Now we will have greater reach and ability to build on each team’s respective expertise to deliver products and performance to a global client base.”

Brian Gevry will serve as Chairman and CEO of the combined parent entity, and Gavin Tait, Amber’s current CEO, will continue to serve as the head of Amber and oversee the Infrastructure business globally, reporting to Brian Gevry.

“We are very excited about integrating with Boyd Watterson and the long-term investment outlook this alignment brings to our customers,” said Tait. “Both firms have a keen focus on delivering outstanding client service and proven expertise in partnering with governments around the world. The planned combination will create greater scale for Amber to grow its global infrastructure business, including US Infrastructure opportunities, while bringing new opportunities for Boyd Watterson’s clients.”

The transaction is subject to Boyd Watterson’s and Amber’s respective client and investor consent processes as well as UK FCA consent and other customary regulatory approvals.

Transaction Rationale

Boyd Watterson’s and Amber’s clients, partners, and employees should benefit significantly from the enhanced scale of the combined, global platform underpinned by a diversified revenue base, expanded product opportunities, and enhanced investment acumen. In summary, the transaction:

  • Provides a robust business model for both companies by enhancing the size and scale of both organizations to the benefit of their respective clients.
  • Creates broader scope with a diversified investment platform enhancing Boyd Watterson’s and Amber’s shared heritage as long-term, trusted partners to clients, government entities, tenants, employees, and investors.
  • Combines two teams with demonstrated track record and deep expertise in their respective, government-linked sectors.
  • Combines culturally aligned partners with like-minded management.
  • Expands global reach and provides new investment opportunities and access to capital.
  • Provides opportunities to strategically enhance systems and share business best practices.

Advisors

For Boyd Watterson, Berkshire Global Advisors served as financial advisor and Goodwin Procter LLP served as legal advisor. Dechert LLP served as legal advisor to Amber and Hunt. Milbank LLP served as legal advisor to Amber’s minority shareholders.

About Boyd Watterson

Founded in 1928 by its predecessor firm, Boyd Watterson Asset Management, LLC (Boyd) is a leading real estate and fixed income investment manager. Headquartered in Cleveland, Ohio, Boyd employs 130 employees in seven offices across the US. Boyd manages c.US$18.2bn of AUM, through separately managed accounts and a number of funds with real estate and fixed income strategies. www.boydwatterson.com

About Amber Infrastructure Group

Amber is a specialist international investment manager, focused on investment origination, asset management and fund management. Amber currently manages or advises 9 funds (2 listed and 7 private) with over £5billion (c.$6billion) in funds under management. With a presence across 12 countries, Amber manages 175 infrastructure investments representing total assets under management of £14 billion (c.$17.5billion). Amber’s core business focuses on managing infrastructure assets across the public, transport, energy, digital and demographic infrastructure sectors internationally. Amber is headquartered in London with offices in Europe, North America, Australia and New Zealand. Amber employs over 180 professionals globally. www.amberinfrastructure.com

About Hunt Companies

Hunt Companies is a family-owned principal investment firm founded in 1947 based in El Paso, TX with interests in the real estate, infrastructure and financial services sectors. As an owner operator with a strong investment platform and financial structuring expertise, Hunt develops lasting relationships to create value for its investors, clients, employees and communities. The company and its affiliates are committed to promoting community growth and a sustainable future through our business practices, purpose driven investment and charitable giving. www.huntcompanies.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Carolyn Baker
SVP Corporate Communications
Hunt Companies
carolyn.baker@huntcompanies.com
m: +1 856/298-2036

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PMC Biogenix Announces Expansion and Restructure21.6.2024 23:00:00 CEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 22:58:00 CEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 22:30:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 22:00:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions21.6.2024 21:45:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive results in the VX-880 trial and reinforce the transformative potential of this therapy. At baseline, all patients in the study had undetectable fasting C-peptide (a marker of endogenous insulin secretion), a history of recurrent SHEs in the year prior to screening, and required an average of 39.3 (min, max; 19.8, 52.0) units of insulin per day. Following a single infusion of VX-880 at the full dose, all 12 patients demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90. At the latest visi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye